subgroups is BRAF -mutated ( BRAF mt) CRC. BRAF mutations are present in roughly 10% of patients with mCRC 2 and portend a particularly unfavorable prognosis, with a median survival for patients with metastatic disease of <12 months. 3 , 4 BRAF mt mCRC
Search Results
Real-World Outcomes of Patients With BRAF-Mutated Metastatic Colorectal Cancer Treated in the United States
Andrew Trunk, Matthew Braithwaite, Christopher Nevala-Plagemann, Lisa Pappas, Benjamin Haaland, and Ignacio Garrido-Laguna
Targeting BRAF Mutations in High-Grade Neuroendocrine Carcinoma of the Colon
Jarred Burkart, Dwight Owen, Manisha H. Shah, Sherif R. Z. Abdel-Misih, Sameek Roychowdhury, Robert Wesolowski, Sigurdis Haraldsdottir, Julie W. Reeser, Eric Samorodnitsky, Amy Smith, and Bhavana Konda
the need to develop effective targeted therapies that can produce durable responses. Targetable genetic features of high-grade NECs have not been comprehensively described. In a recent case series, Klempner et al 2 reported BRAF mutations in 9% of
Response to Dabrafenib Plus Trametinib in a Patient With an Uncommon Activating BRAF Mutation: A First in Non–Small Cell Lung Cancer
John A. Sharp, Daniel Jones, Julia K. Rotow, Panos M. Fidias, Erin Bertino, and Dwight H. Owen
cancer. 5 BRAF mutations occur in 4% of all non–small cell lung cancer (NSCLC) cases; however, 50% are non-V600 mutations. 6 BRAF mutations are categorized into 3 classes depending on their effects on kinase activity, RAS-dependency, and
Differential Radiographic Appearance of BRAF V600E–Mutant Metastatic Colorectal Cancer in Patients Matched by Primary Tumor Location
Chloe E. Atreya, Claire Greene, Ryan M. McWhirter, Nabia S. Ikram, I. Elaine Allen, Katherine Van Loon, Alan P. Venook, Benjamin M. Yeh, and Spencer C. Behr
high degree of CpG island methylation (CIMP-H). 3 – 10 BRAF mutations are more frequent in women, older patients, and in whites compared with Asians or blacks with CRC. 2 , 11 , 12 Importantly, BRAF V600E–mutated mCRC is associated with a poor
BRAF Mutations in Colorectal Cancer: Clinical Relevance and Role in Targeted Therapy
Rona Yaeger and Leonard Saltz
a V600E BRAF mutation, and can that mutation be targeted for therapeutic advantage? BRAF as a Prognostic and Predictive Marker From a prognostic perspective, it is clear that BRAF mutations confer a particularly poor prognosis, regardless of
CRE24-044: Response to Dabrafenib and Trametinib in a Patient With an Uncommon Activating BRAF Mutation: A First in Metastatic Non–Small Cell Lung Cancer
John Sharp, Daniel Jones, Julia Rotow, Panos Fidias, Erin Bertino, and Dwight Owen
Introduction: 4% of patients with non-small cell lung cancer (NSCLC) have BRAF mutations. 50% are class I variants, affecting the V600 codon, for which BRAF/MEK inhibitors (BRAF/MEKi) are approved. Optimal therapy for class II variants (non
Unusual Adverse Events in a Patient With BRAF-Mutated Non–Small Cell Lung Cancer Treated With BRAF/MEK Inhibition
Rohan Maniar, Stephanie M. Gallitano, Sameera Husain, Golnaz Moazami, Michael J. Weiss, and Catherine A. Shu
% to 85% of all cases. 1 , 2 BRAF mutations have been described in a number of malignancies, including melanoma and colon cancer, and account for approximately 2% to 4% of NSCLC. 3 Although a number of BRAF mutations have been identified, clinical
Mutation Testing and Adjuvant Systemic Therapy in Cutaneous Melanoma
Anthony J. Olszanski
.2019. Available at NCCN.org . Approximately half of all melanomas harbor a BRAF mutation; most commonly, these mutations are activating BRAF V600E or V600K mutations (only ∼8% of BRAF mutations are non-V600E/K). The second most common genomic alteration in
Cotreatment of Hairy Cell Leukemia and Melanoma With the BRAF Inhibitor Dabrafenib
James S. Blachly, Gerard Lozanski, David M. Lucas, Michael R. Grever, Kari Kendra, and Leslie A. Andritsos
second melanoma resection were sent to the molecular diagnostics laboratory at The Ohio State University where BRAF mutation testing was performed. Briefly, in a Clinical Laboratory Improvement Amendments–certified procedure, the genomic DNA was
Targeted Therapy for Patients With Metastatic Non–Small Cell Lung Cancer
Karen L. Reckamp
Conference. 1 The list of mutations with approved targeted therapies includes EGFR mutations (present in 30%–40% of Asians 2 and 10%–20% of Caucasians), 3 ALK rearrangements (present in up to 7%), ROS1 rearrangements (1.7%), and BRAF mutations
